Migraine-Specific Quality-of-Life Questionnaire (MSQ) Version 2.1 Score Improvement in Japanese Patients with Episodic Migraine by Galcanezumab Treatment: Japan Phase 2 Study

• Main Authors: Shibata M, Nakamura T, Ozeki A, Ueda K, Nichols RM
• Format: Article
• Language: English
• Published: Dove Medical Press 2020-12-01
• Series: Journal of Pain Research
• Subjects: mesh: preventive therapy; quality of life
• Online Access: https://www.dovepress.com/migraine-specific-quality-of-life-questionnaire-msq-version-21-score-i-peer-reviewed-article-JPR

Mamoru Shibata,1 Tomomi Nakamura,2 Akichika Ozeki,2 Kaname Ueda,2 Russell M Nichols3 1Department of Neurology, Tokyo Dental College Ichikawa General Hospital, Ichikawa, Japan; 2Medicines Development Unit Japan and Medical Affairs, Eli Lilly Japan K.K., Kobe, Japan; 3Global Medical Affairs, Eli Lilly and Company, Indianapolis, IN, USACorrespondence: Tomomi NakamuraMedicines Development Unit Japan and Medical Affairs, Eli Lilly Japan K.K., 5-1-28 Isogamidori, Chuo-Ku, Kobe 651-0086, JapanTel [phone]Email [e-mail]: Evaluate changes from baseline in health-related quality of life (QoL) in Japanese patients with episodic migraine receiving preventive treatment with galcanezumab (GMB).Patients and Methods: Preventive treatments for migraine have been shown to improve QoL, but few clinical trials have examined QoL outcomes in Japanese patients. This phase 2, randomized, double-blind, placebo-controlled study was conducted at 40 centers in Japan. Patients aged 18– 65 years with episodic migraine (4– 14 monthly migraine headache days) received GMB 120 mg (n=115), 240 mg (n=114), or placebo (PBO, n=230) as monthly subcutaneous injections for 6 months. QoL was measured monthly using the Migraine-Specific Quality-of-Life Questionnaire (MSQ) version 2.1. Prespecified analyses were differences between GMB and PBO for change from baseline in all 3 domains of the MSQ and MSQ-Total, for each month and the average over Months 4– 6.Results: Treatment with GMB significantly increased MSQ scores from baseline vs PBO. Average change ± SE from baseline across Months 4– 6 was 10.12± 0.72 (PBO), 17.13± 1.03 (GMB 120 mg; P< 0.001), and 15.91± 1.03 (GMB 240 mg; P< 0.001) for MSQ Role Function-Restrictive; 4.80± 0.65 (PBO), 9.64± 0.93 (GMB 120 mg; P< 0.001), and 8.35± 0.93 (GMB 240 mg; P< 0.05) for MSQ Role Function-Preventive (MSQ-RFP); 3.46± 0.77 (PBO), 10.04± 1.10 (GMB 120 mg; P< 0.001), and 7.73± 1.10 (GMB 240 mg; P< 0.05) for MSQ Emotional Function, and 7.14± 0.67 (PBO), 13.46± 0.95 (GMB 120 mg; P< 0.001), and 11.98± 0.95 (GMB 240 mg; P< 0.001) for MSQ-Total. Significantly greater improvement in scores in all MSQ domains and MSQ-Total was observed for both GMB doses vs PBO at Month 1 and was maintained for Months 1– 6 (excluding Month 5 for MSQ-RFP).Conclusion: Preventive treatment with GMB 120 mg/240 mg improves MSQ scores in Japanese patients with episodic migraine. Improvements were seen within the first month and maintained for 6 months and are similar to those seen in global studies enrolling primarily Caucasian patients.Clinical Trial Registration: ClinicalTrials.gov, NCT02959177 (registered November 7, 2016).Keywords: MeSH: preventive therapy, quality of life